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Abstract. The European Dialysis and Transplantation
Association—European Renal Association (EDTA-
ERA) Registry conducted a special study on anaemia
in dialysis patients because it seemed important to
elucidate the various factors that influence the degree
of anaemia and the use of regular transfusions in
dialysis patients before the introduction of recombinant
human erythropoietin (rHuEpo) for larger groups of
patients. In a 20% sample of all patients recorded to
have been dialysed throughout 1987, statistically signi-
ficant associations could be found by multifactorial
analysis between haemoglobin (Hb) concentration and
age, sex, primary renal disease, type of treatment,
hours of dialysis per week, and number of years on
renal replacement therapy. The type of dialyser mem-
brane did not seem to play a role (although there was
weak evidence of an effect of the dialyser). Mean Hb
concentration for dialysis patients differed between
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countries as did the transfusion policy. In view of the
high costs of the rHuEpo treatment and potential side-
effects, factors such as method of dialysis and hours
of haemodialysis per week should be taken into consid-
eration in the treatment of anaemia in dialysis patients.
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Introduction
The degree of anaemia in progressive renal failure
increases as the glomerular filtration rate declines [1]
and in patients treated by either haemodialysis or
peritoneal dialysis, anaemia is almost invariably pre-
sent. Diminished erythropoietin production seems to
be the important pathogenetic factor, although other
factors such as circulating inhibitors of erythropoiesis
and decreased red cell survival have been described.
Anaemia contributes considerably to morbidity and
impairs the quality of life in patients on dialysis, and
the introduction of rHuEpo was a major breakthrough
in the management of patients with end-stage renal
disease [2,3].
Data concerning the influence of dialysis itself on
the prevailing anaemia are conflicting [4,5]. A time-
related increase in haematocrit on maintenance haemo-
dialysis has been described and in some cases has been
associated with concurrent acute or chronic hepatitis
[6,7]. It has often been suggested that acquired renal
cysts may be responsible for an increase in haematocrit,
but recently this correlation has been questioned [8-10].
To investigate transfusion dependency and the influ-
ence of several variables on anaemia in a large group
of dialysis patients the EDTA Registry designed a
special study concerning patients dialysed throughout
1987. In that particular year prescription of rHuEpo
had barely started, and only a few patients in a
minority of centres were receiving the drug. Hence
there were no confounding effects of rHuEpo treat-
ment. The database of the EDTA Registry made it
possible to combine the results obtained in a special
questionnaire with the extensive patient data already
available from the Registry's file.
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Subjects and methods
At the end of 1987 there were 65 200 patients on the Registry
who were alive and had been treated throughout the year
1987 by dialysis (centre haemodialysis, home haemodialysis,
intermittent peritoneal dialysis, or CAPD). Patients were
sorted into random order within each centre in each country.
After sorting, a 20% sample was taken, resulting in 13 040
patients selected. Each centre was sent a questionnaire with
the name or initials of the randomly selected patients. The
doctors responsible for these centres were asked to record
the Hb concentration in December 1987. In addition they
had to indicate for each patient the need of regular transfu-
sion (defined as more than 1 unit of blood per 2-month
interval). Information was also requested regarding bilateral
nephrectomy and treatment with rHuEpo in 1987 and/or in
1988. Routine software tools made it possible to link the
data from the special questionnaire with the other patient
data already available on the Registry's file.
Of the special questionnaires concerning 13040 patients
mailed in January 1989, 8625 were returned by the end of
1989. Of these, 7948 patients had Hb values recorded (92.2%)
whilst 565 (6.6%) patients had to be excluded because of
uncertainty regarding the absence of any changes in method
of RRT during 1987, and another 515 (6%) because they
had undergone bilateral nephrectomy or had been treated
with rHuEpo in 1987. This left 6869 (79.6%) patients for
analysis.
Data on type of dialyser most frequently used during 1987
for each individual, including the type of membrane and its
ultrafiltration characteristics, were available for 4591 patients
on haemodialysis. The variables listed in Table 1 were ana-
lysed by multiple regression against Hb concentration at 31
December 1987 and by logistic regression [11] against the
need for transfusion during 1987.
The multifactorial analyses were carried out using the
statistical package GLIM [12].
Results
Validation of the sampling procedure
Primary renal disease was selected as the profile charac-
teristic to test the validity of the sampling procedure.
In Figure 1 the distribution of primary renal disease
in patients sampled can be compared to the distribution
in all patients eligible for the sample. That primary
renal diseases are similarly distributed in both groups
Table 1. Variables studied in the multifactorial regression analyses
Country of treatment
Sex
Age
Primary renal disease
Type of initial treatment
Type of most recent treatment
Length of time since start of treatment
Length of time on most recent treatment
Need for regular transfusions
Number of dialysis sessions per week
Hours of dialysis per week
Membrane type of dialyser
Ultrafiltration characteristics of the dialyser
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diabetic nephr
cvstic diseases
unknown aetiology
pyelonephritis
glomerulonephritis
all patients
sample analysed
percent
Fig. 1. Proportional distribution of different renal diseases among
all patients dialysed throughout 1987 and among 6869 patients
entered into the analyses.
of patients indicates that no bias for this factor was
created by the sampling procedure.
Countries
In Table 2 the mean Hb concentrations are given
according to the countries. A wide range is seen
between countries such as the then German Democratic
Republic and Czechoslovakia for whom mean Hb
concentrations under 80 g/1 were recorded, whereas
Table 2. Mean haemoglobin concentration according to country.
Countries with less than 10 patients were excluded
Austria
Belgium
Czechoslovakia
Denmark
Finland
France
Germany (East)
Germany (West)
Greece
Hungary
Ireland
Israel
Italy
Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Turkey
UK
Yugoslavia
Luxembourg
Bulgaria
Cyprus
Tunisia
Egypt
Libya
All
n
88
224
123
39
38
1118
175
1335
110
58
31
78
1160
108
11
85
187
913
83
137
24
311
253
12
77
14
38
17
13
6869
Hb (g/dl)
Mean±SD
83.8+17.2
88.4+16.5
78.3 ±14.2
89.4+19.3
90.7±21.1
91.5±20.5
78.8+15.4
90.5+19.2
91.9± 18.9
84.9+15.9
83.6+17.7
85.9± 18.1
88.4± 19.6
87.7 ±22.2
90.6 ±12.0
87.6±18.5
87.6 ±20.4
89.0 + 21.3
86.6+18.7
91.8 + 22.1
86.9+19.3
90.8 ±21.9
82.8± 18.2
87.8 ±14.6
84.3+14.9
80.4+16.2
87.4 + 21.5
75.4± 17.8
75.3± 16.6
88.7±19.9
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France, the then Federal Republic of Germany, Greece,
Switzerland, United Kingdom, and Scandinavian coun-
tries had mean Hb concentrations over 90 g/1.
Age and sex
Hb values were higher in males on renal replacement
therapy (RRT) and tended to increase with age for
both sexes (Figure 2). This is also reflected by the
transfusion rate: 21% of all females were regularly
transfused versus 13% of men.
Primary renal disease
The relationship between anaemia and primary renal
disease is depicted in Table 3. Patients with polycystic
kidney disease (ADPKD) showed significantly higher
Hb concentrations. For all the other primary renal
diseases no significant differences in haemoglobin con-
centration were observed. This is confirmed by the fact
that regular transfusion was given to only 7% of
patients with ADPKD, whereas 32% of patients with
hereditary or familial nephropathy other than ADPKD
received regular transfusions.
HI) (B/l)
male (mean = 92 g/l)
female (mean - 84 g/l)
30 40
age
50
Fig. 2. Mean haemoglobin concentration according to sex and age.
Table 3. Mean haemoglobin concentration for selected primary
renal diseases
Primary renal disease
Aetiology uncertain
Glomerulonephritis
Severe nephrotic syndrome in children
Pyelonephritis/interstitial nephritis
Analgesic nephropathy
Adult polycystic kidney disease
Diabetic nephropathy
Renal vascular disease
Congenital/hereditary renal disease
All
Hb (g/l)
Mean + SD
86.5+18.9
87.6+19.8
78.2± 18.8
86.1 + 18.6
86.3+17.9
01.6 + 21.4
90.2+17.9
88.5+17.6
88.5±22.8
88.7±19.9
n
844
1972
5
1336
209
603
424
625
86
6860
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Method of treatment and time spent on renal
replacement therapy
In patients for whom CAPD was recorded as the most
recent mode of RRT the mean Hb concentration was
96.1 g/l. Home haemodialysis patients displayed hae-
moglobin concentrations with a mean of 95.1 g/l. For
hospital haemodialysis patients the mean Hb concen-
tration was lower at 87.4 g/l, while IPD patients (n =
27) had a mean haemoglobin concentration of 89.9 g/l.
In Table 4 the proportion of patients treated with
hospital haemodialysis, home haemodialysis, CAPD,
or IPD is shown for four ranges of Hb concentrations,
showing that patients with Hb concentrations above
100 g/l were more likely to be on home haemodialysis
or CAPD. The same association was found regarding
the need for transfusion which was lower in patients
on home haemodialysis (9%) and in patients on CAPD
(7%) compared with 18% of patients on hospital
haemodialysis.
In Figure 3 the influence of length of time on RRT
on Hb concentrations and need for transfusion is
shown. Both variables were significantly related to time
Table 4. Percentage of patients in four different ranges of Hb
concentration according to mode of treatment on 31 December 1987
Hbg/1 <60 60-79 80-100 > 100 n=100%
Centre
HD
Home
HD
CAPD
4.0
3.2
1.3
36.8
27.6
25
36.8
32.4
34.8
22.4
36.8
38.8
5804
535
505
HI) ± SD g/l
l-<
percent
2 0 -
1 0 -
n _
20
•1
1J
2 2-<3
transfused
19
•
•LL
3-<5
18
•
•1
5- < 1 O
15
•L
1 0 - < l 5
9
£15
11J
2-<3 3-<5 5-<10
Years on treatment
Fig. 3. Mean haemoglobin concentration and percentage of patients
needing regular transfusion related to length of time on treatment
in years.
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on RRT. In a more restricted analysis the influence of
time spent on the most recent method of dialysis also
showed a positive correlation with Hb concentration.
There was a mean increase of 0.74 g/1 for every year
of treatment for all dialysis modalities combined
(/*< 0.001), although the relationship had a correlation
coefficient of only 0.12, indicating the important influ-
ence of other parameters.
Haemodialysis schedule and type ofdialyser membrane
While patients who were dialysed three times a week
had higher haemoglobin concentrations than those
dialysed twice a week, and this was also reflected by
the need for transfusion (Figure 4), multifactorial
analysis disclosed that the variable 'times per week'
was itself not significantly correlated with Hb concen-
tration, in contrast to the variable 'number of hours
per week'. Hence three-times-weekly dialysis was asso-
ciated with higher Hb concentrations because these
patients were treated for more hours per week than
those on twice-weekly dialysis.
The influence of the number of hours dialysis per
week is apparent from Figure 5. In this study 11 or
more hours of dialysis per week is associated with a
steadily increasing Hb concentration. The variables
'mean blood flow/min' or 'dialyser area' were not
studied.
To determine the effects of different types of dia-
lysers, patients were grouped according to whether
they had been treated most commonly with cellulose
as opposed to non-cellulose membranes. This compar-
ison did not yield any difference (mean Hb concentra-
Hb (g/l)
<8 8 9 10 11 12 13 14 15 > 1 5
hours/week
Fig. 5. Mean haemoglobin concentration related to number of hours
haemodialysis per week.
tion 88.3 g/l for patients on cellulose versus 88.5 g/l for
patients on non-cellulose membranes). In both groups
the identical proportion of 17% needed regular
transfusions.
A potential effect of porosity of the membrane was
tested by grouping patients according to the ultrafiltra-
tion capacity of their dialyser. Patients dialysed with
low-ultrafiltration dialysers (< 10 ml/h/mmHg TMP)
were compared to those with medium ultrafiltration
(10-20 ml/h/mmHg TMP) and to those dialysed with
high ultrafiltration (> 20 ml/h/mmHg TMP). Again,
no significant association was obtained between ultra-
filtration capacity and either the haemoglobin concen-
tration (P=0.10) or the need for transfusion (P> 0.10).
no
Hb±SDg/l
30
1 2
percent transfused
2 0 -
1 0 -
2 3 4
Dialysis sessions per week
Fig. 4. Mean haemoglobin concentration and percentage of patients
needing regular transfusion related to number of dialysis sessions
per week.
Discussion
Many factors have been associated with improvement
of anaemia in patients undergoing dialysis for end-
stage renal disease. A progressive increase in haemato-
crit has been attributed to improved dialytic technique,
to CAPD, to acquired cystic kidney disease, to hepat-
itis, to parathyroidectomy, and to treatment with
androgens [4-10]. The introduction of rHuEpo enabled
doctors partially to correct the normochromic normo-
cytic anaemia complicating renal failure [2,3]. The
efficacy of erythropoietin treatment is beyond dispute;
however, optimizing dialysis treatment may minimize
the requirement for the costly drug, allowing a reduc-
tion of the dosage needed for correction of renal
anaemia.
This study was designed to help fill the gap in our
knowledge regarding the influence of various factors
on anaemia in dialysis patients using a representative
sample drawn from our large database.
Significant associations were found between Hb con-
centration and primary renal disease, age, sex, type of
last recorded treatment, length of time on treatment,
number of dialysis sessions per week and hours of
dialysis per week (although patients on three-times-
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weekly dialysis appeared to have a higher Hb concen-
tration because of the larger number of dialysis hours
per week).
The greater Hb concentrations recorded for patients
on home haemodialysis and CAPD probably reflect
patient selection and freedom from complicating ill-
ness. There have been reports that claim a beneficial
role of CAPD itself on the anaemia of dialysis patients;
an increase in red cell mass is reported by most authors
[13,14] whereas a decrease in plasma volume is infre-
quently reported [13]. There is no evidence for increased
erythropoietin secretion in CAPD patients but there
may be removal of inhibitors of erythropoiesis [15,16].
Increased red cell longevity is reported in several
studies and may also contribute to the lesser degree of
anaemia in CAPD patients [14].
The increase of Hb concentration with length of
treatment could be explained simply by an increased
mortality of the intrinsically less well, and so more
anaemic, patients. However, an increase in Hb concen-
tration has also been observed in dialysis patients with
liver disease [6,7] and in association with acquired
renal cyst formation [8], although the latter mechanism
has been disputed [10].
One of the salient findings borne out by this study
is the positive correlation between Hb concentration
and number of hours spent on haemodialysis per week.
That Hb concentration was greater in patients who
received more than 12 h dialysis per week implies a
role for the amount and the efficacy of dialysis on the
degree of anaemia.
In the present study the use of dialysers with non-
cellulose membranes and high ultrafiltration capacity
was not associated with a higher Hb concentration.
Of all patients evaluated, 16.5% needed regular
transfusion, as expected. Among the more anaemic
patients with Hb concentrations between 60 and 80 g/1
the proportion receiving regular transfusion was 28%,
of the less anaemic patients with Hb concentrations
between 80 and 100 g/1 only 12% were regularly trans-
fused. Transfusion policy may not always have fol-
lowed strict rules, as financial, political, medical, and
religious reasons exist which may inhibit blood transfu-
sion, or even encourage the doctor to transfuse a
patient to a higher Hb than his counterparts.
The risks associated with transfusion such as sensit-
ization, transmission of infectious diseases, and pos-
sibly transfusion-induced erythroid suppression,
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should be weighed against the cost and side-effects of
erythropoietin treatment. RHuEpo corrects anaemia
in dialysis patients but this study demonstrates that
rHuEpo should be used in conjunction with those
management options which are themselves correlated
with lessening of anaemia and reduced need for regular
transfusion.
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